The U.K. drugmaker’s strength in the segment allowed it to offset a declining vaccines revenue and a flat performance in general medicines.
About The Author
The U.K. drugmaker’s strength in the segment allowed it to offset a declining vaccines revenue and a flat performance in general medicines.
